| 周解平,高宁,漆仲禹,等.ArcherQA三维剂量验证系统在VMAT计划剂量验证的应用[J].中华放射医学与防护杂志,2025,45(6):551-557.Zhou Jieping,Gao Ning,Qi Zhongyu,et al.Application of the ArcherQA 3D dosimetric verification system in dosimetric verification of VMAT plans[J].Chin J Radiol Med Prot,2025,45(6):551-557 |
| ArcherQA三维剂量验证系统在VMAT计划剂量验证的应用 |
| Application of the ArcherQA 3D dosimetric verification system in dosimetric verification of VMAT plans |
| 投稿时间：2024-09-24 |
| DOI：10.3760/cma.j.cn112271-20240924-00379 |
| 中文关键词: 蒙特卡罗 剂量验证 容积弧形调强放射治疗 |
| 英文关键词:Monte Carlo algorithm Dosimetric verification Volumetric Modulated Arc Therapy |
| 基金项目:国家自然科学基金项目(12275372);安徽省重点研究与开发计划(2023s07020020);中国科学技术大学双一流医学物理与生物医学工程交叉学科平台(YD2140000601);2020年中国科学技术大学新医学创新团队项目(YD2140002002) |
|
| 摘要点击次数: 5 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的 应用ArcherQA三维剂量验证系统进行容积弧形调强放射治疗(VMAT)计划剂量验证。方法 回顾性收集中国科学技术大学附属第一医院肿瘤放疗科2023年7月至2024年3月196例VMAT治疗计划的ArcCHECK测量验证结果,采用基于快速蒙特卡罗算法的ArcherQA系统进行独立的剂量计算验证。比较ArcherQA与ArcCHECK剂量验证的γ通过率、分析两者的相关性并作线性回归拟合;计算ArcherQA系统检测ArcCHECK测量验证结果阳性的γ通过率阈值及检测的特异性;基于该γ通过率阈值,另选50例VMAT计划作为测试集评价ArcherQA系统对测量验证阳性结果的检测能力。结果 VMAT计划的ArcherQA和ArcCHECK剂量验证的平均γ通过率分别为97.28%和96.57% (3%/3 mm,TH=10%), 两者的相关性系数为0.71 (P<0.01),线性拟合系数为0.54 (R2=0.51)。当ArcCHECK测量验证的γ通过率设定为90% (3%/2 mm, TH=10%)时,则需要调整ArcherQA的γ通过率阈值至94.8%,才能完全检测出ArcCHECK测量验证阳性的VMAT计划,检测的特异性参数为67.8%。基于该γ通过率阈值ArcherQA能完全检测出测试集测量验证的阳性病例。结论 ArcherQA系统通过确定合适的γ通过率阈值能够快速准确地检测出放疗剂量潜在不精确的VMAT治疗计划,保证治疗精度,提高工作效率。 |
| 英文摘要: |
| Objective To rapidly and accurately detect volumetric modulated arc therapy (VMAT) plans with potentially inaccurate radiation doses. Methods The measurement-based dosimetric verification result of 196 VMAT plans obtained using ArcCHECK phantoms were retrospectively collected. Independent dosimetric calculation and verification were conducted for these plans using the ArcherQA system based on a fast Monte Carlo algorithm. The gamma passing rates of dosimetric verification using ArcCHECK phantom and the ArcherQA system were compared, followed by their correlation analysis and linear regression fitting. The ArcherQA system's gamma passing rate threshold used to detect positive dosimetric verification result obtained using ArcCHECK phantoms, as well as the specificity of the detection, were calculated. Based on this gamma passing rate threshold, another 50 VMAT plans were selected as a test set to assess the ArcherQA system's ability to detect positive measurement-based dosimetric verification result. Results The average gamma passing rates for the dosimetric verification of the VMAT plans using the ArcherQA system and ArcCHECK phantoms were 97.28% and 96.57% (3%/3 mm, TH=10%), respectively. Both rates had a correlation coefficient of 0.71 (P < 0.01) and a linear fitting coefficient of 0.54 (R2=0.51). When the gamma passing rate for dosimetric verification using ArcCHECK phantoms was set at 90% (3%/2 mm, TH=10%), the gamma passing rate threshold for dosimetric verification using the ArcherQA system should be adjusted to 94.8% to detect all VMAT plans with positive dosimetric verification result obtained using ArcCHECK phantoms, with a specificity of 67.8%. Using this threshold, the ArcherQA system detected all VMAT plans in the test set for which ArcCHECK phantom-based measurement yielded positive dosimetric verification result. Conclusions By determining an appropriate gamma passing rate threshold, the ArcherQA system can rapidly and accurately detect VMAT plans with potentially inaccurate doses, thus ensuring treatment accuracy and improving work efficiency. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|